RCUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcus Biosciences Inc (RCUS) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there are some positive catalysts, the overall sentiment, technical indicators, and financial performance suggest a cautious approach. The stock is better suited for monitoring rather than immediate investment.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 49.338, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 23.046, with key support at 21.682 and resistance at 24.409. This suggests limited upside potential in the short term.
Hedge funds are significantly increasing their positions, with a 186.42% increase in buying activity over the last quarter. Analysts from Citi and Leerink recently raised their price targets to $45 and $49, respectively, with positive ratings.
Wells Fargo and Morgan Stanley downgraded the stock to Equal Weight, citing potential headwinds from upcoming data readouts and limited differentiation for key products. No recent news or significant insider activity to drive momentum.
In Q4 2025, revenue increased by 26.92% YoY to $33 million, and net income improved by 12.77% YoY but remains negative at -$106 million. EPS dropped by -13.59% YoY to -0.89. Gross margin remains strong at 100%. While revenue growth is promising, the company is still unprofitable, which may concern long-term investors.
Recent analyst ratings are mixed. Citi and Leerink are bullish with raised price targets, while Wells Fargo and Morgan Stanley downgraded the stock due to concerns over upcoming data readouts and limited differentiation for key products.
